AbbVie Reports Q1 Revenue Growth Amidst GAAP Profit Decline

AbbVie (ABBV) has announced its financial results for the first quarter of 2026, highlighting a divergence between top-line growth and bottom-line GAAP profitability. The pharmaceutical giant demonstrated strong sales momentum, though GAAP-level earnings faced a year-over-year contraction. Revenue for the period climbed to $15.01 billion, representing a 12.5% increase from the $13.34 billion reported in the first quarter of the previous year. This growth suggests continued demand and successful market penetration for the company's product portfolio. On a GAAP basis, the company's bottom line dropped to $695 million, or $0.39 per share, compared to $1.28 billion, or $0.72 per share, in the prior-year period. Despite this GAAP decline, AbbVie reported adjusted earnings of $4.71 billion, or $2.65 per share, providing a more optimistic view of its core operational performance. Looking forward, the company has provided full-year earnings per share (EPS) guidance in the range of $14.08 to $14.28. Market participants will likely weigh the GAAP profit dip against the robust revenue growth and adjusted earnings to determine the stock's near-term trajectory.